Thomas W Geisbert

Summary

Affiliation: University of Texas Medical Branch
Country: USA

Publications

  1. ncbi request reprint Animal challenge models of henipavirus infection and pathogenesis
    Thomas W Geisbert
    Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
    Curr Top Microbiol Immunol 359:153-77. 2012
  2. pmc Pathogenesis of Lassa fever in cynomolgus macaques
    Lisa E Hensley
    Virology, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    Virol J 8:205. 2011
  3. pmc Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections
    Thomas W Geisbert
    Galveston National Laboratory, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77550 0610, USA
    J Infect Dis 204:S1075-81. 2011
  4. pmc Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine
    Kathleen M Daddario-DiCaprio
    Virology Division, USAMRIID, Fort Detrick, MD 21702 5011, USA
    J Virol 80:9659-66. 2006
  5. pmc A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge
    Chad E Mire
    Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA
    J Virol 88:4624-31. 2014
  6. ncbi request reprint Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment
    Kathleen M Daddario-DiCaprio
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    Lancet 367:1399-404. 2006
  7. ncbi request reprint Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever
    Lisa E Hensley
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    J Infect Dis 196:S390-9. 2007
  8. ncbi request reprint Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2
    Thomas W Geisbert
    Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, MD, USA
    J Infect Dis 196:S372-81. 2007
  9. ncbi request reprint Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Infect Dis 193:1650-7. 2006
  10. pmc Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Virol 84:10386-94. 2010

Collaborators

Detail Information

Publications40

  1. ncbi request reprint Animal challenge models of henipavirus infection and pathogenesis
    Thomas W Geisbert
    Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
    Curr Top Microbiol Immunol 359:153-77. 2012
    ....
  2. pmc Pathogenesis of Lassa fever in cynomolgus macaques
    Lisa E Hensley
    Virology, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    Virol J 8:205. 2011
    ..Here, we performed a pilot study to begin to understand the progression of LASV infection in nonhuman primates...
  3. pmc Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections
    Thomas W Geisbert
    Galveston National Laboratory, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77550 0610, USA
    J Infect Dis 204:S1075-81. 2011
    ..Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections...
  4. pmc Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine
    Kathleen M Daddario-DiCaprio
    Virology Division, USAMRIID, Fort Detrick, MD 21702 5011, USA
    J Virol 80:9659-66. 2006
    ..These data suggest that the VSVDeltaG/MARVGP-Musoke vaccine should be sufficient to protect against all known MARV strains...
  5. pmc A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge
    Chad E Mire
    Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA
    J Virol 88:4624-31. 2014
    ..Success of the recombinant subunit vaccine in AGMs provides pivotal data in supporting its further preclinical development for potential human use...
  6. ncbi request reprint Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment
    Kathleen M Daddario-DiCaprio
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    Lancet 367:1399-404. 2006
    ..We aimed to test the efficacy of a replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever...
  7. ncbi request reprint Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever
    Lisa E Hensley
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    J Infect Dis 196:S390-9. 2007
    ..The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF...
  8. ncbi request reprint Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2
    Thomas W Geisbert
    Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, MD, USA
    J Infect Dis 196:S372-81. 2007
    ....
  9. ncbi request reprint Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Infect Dis 193:1650-7. 2006
    ..Here, we describe the development of a potential therapy for EBOV infection that is based on small interfering RNAs (siRNAs)...
  10. pmc Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Virol 84:10386-94. 2010
    ....
  11. pmc Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells
    Thomas W Geisbert
    United States Army Medical Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Am J Pathol 163:2371-82. 2003
    ..Together, these data suggest that coagulation abnormalities associated with EBOV HF are not the direct result of EBOV-induced cytolysis of endothelial cells, and are likely triggered by immune-mediated mechanisms...
  12. ncbi request reprint Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus
    Thomas Larsen
    Pathology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    J Infect Dis 196:S323-8. 2007
    ..We suggest that treatment extended the time course of the disease and permitted the virus to infect tissues not usually affected in the typical model...
  13. doi request reprint Cellular immune response to Marburg virus infection in cynomolgus macaques
    Elizabeth A Fritz
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    Viral Immunol 21:355-63. 2008
    ..IL-6 production was detected late in the infection in CD14(+) spleen cells. These results suggest a robust innate immune response to MARV; however, this response was delayed relative to the infection...
  14. pmc Development of a new vaccine for the prevention of Lassa fever
    Thomas W Geisbert
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    PLoS Med 2:e183. 2005
    ..Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge...
  15. ncbi request reprint Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys
    Thomas W Geisbert
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
    Lancet 362:1953-8. 2003
    ..Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus...
  16. pmc Framework for leadership and training of Biosafety Level 4 laboratory workers
    James W Le Duc
    Institute for Human Infections and Immunity, Galveston National Laboratory, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555 0610, USA
    Emerg Infect Dis 14:1685-8. 2008
    ..Although standardized certification of training does not formally exist, the directors agreed that facility-specific, time-limited documentation to recognize specific skills and experiences of trained persons is needed...
  17. ncbi request reprint Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates
    Peter B Jahrling
    Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, MD, USA
    J Infect Dis 196:S400-3. 2007
    ..These data cast further doubt on the value of passive immunotherapy for the treatment of EBOV infection...
  18. pmc Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Virol 85:4222-33. 2011
    ..Increases in efficacy are paralleled by substantial increases in T- and B-cell responses to EBOV GP. These results suggest that Ad26 and Ad35 vectors warrant further development as candidate vaccines for EBOV...
  19. ncbi request reprint Lymphocyte death in a mouse model of Ebola virus infection
    Steven B Bradfute
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    J Infect Dis 196:S296-304. 2007
    ..In a mouse model of ZEBOV infection, lymphocyte death is a prominent finding; however, the mechanism of death and the lymphocyte subsets that are targeted remain unknown...
  20. doi request reprint Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques
    Lisa E Hensley
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    J Infect Dis 204:S1021-31. 2011
    ..In this study we evaluated the progression of MARV infection in nonhuman primates...
  21. pmc Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection
    Thomas W Geisbert
    United States Army Medical Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Am J Pathol 163:2347-70. 2003
    ..The sequence of pathogenetic events identified in this study should provide new targets for rational prophylactic and chemotherapeutic interventions...
  22. pmc Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates
    Chad E Mire
    Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
    PLoS ONE 9:e94355. 2014
    ..Importantly, these data are the first to show 100% protective efficacy against any high dose filovirus challenge beyond 8 weeks after final vaccination. These findings demonstrate the durability of VSV-based filovirus vaccines. ..
  23. ncbi request reprint Immunization strategies against henipaviruses
    Christopher C Broder
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    Curr Top Microbiol Immunol 359:197-223. 2012
    ..Several henipavirus challenge models have been used and recent successes in both active and passive immunization strategies against henipaviruses have been reported which have all targeted the viral envelope glycoproteins...
  24. ncbi request reprint Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques
    Douglas S Reed
    Center for Aerobiological Sciences, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA
    Viral Immunol 17:390-400. 2004
    ....
  25. pmc Inhibition of heat-shock protein 90 reduces Ebola virus replication
    Darci R Smith
    U S Army Medical Research Institute of Infectious Diseases, Virology Division, Fort Detrick, MD, United States
    Antiviral Res 87:187-94. 2010
    ..These results validated that Hsp90 is an important host factor for the replication of filoviruses and suggest that Hsp90 inhibitors may be therapeutically effective in treating EBOV infection...
  26. ncbi request reprint Therapeutic treatment of nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody
    Thomas W Geisbert
    Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550, USA Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA
    Sci Transl Med 6:242ra82. 2014
    ....
  27. pmc Evaluation in nonhuman primates of vaccines against Ebola virus
    Thomas W Geisbert
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Emerg Infect Dis 8:503-7. 2002
    ..The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms...
  28. ncbi request reprint Development of treatment strategies to combat Ebola and Marburg viruses
    Jason Paragas
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Expert Rev Anti Infect Ther 4:67-76. 2006
    ..In this review, select technologies and approaches will be highlighted as part of the critical path for the development of therapeutics to ameliorate the invariably devastating outcomes of human filoviral infections...
  29. ncbi request reprint Ebola and Marburg viruses: pathogenesis and development of countermeasures
    Lisa E Hensley
    Virology Division, U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Curr Mol Med 5:761-72. 2005
    ..In addition, substantial progress has been made in developing recombinant vaccines against these viruses...
  30. ncbi request reprint The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates
    Lisa E Hensley
    Virology Division, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    Thromb Haemost 94:254-61. 2005
    ..Some of the remaining and key unanswered questions relating to the role of the vascular system in the pathogenesis of this disease, that need to be addressed in further research, are highlighted...
  31. pmc Interferon-beta 1a and SARS coronavirus replication
    Lisa E Hensley
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA
    Emerg Infect Dis 10:317-9. 2004
    ..Here, we report that recombinant human interferon-beta 1a potently inhibits SARS coronavirus replication in vitro...
  32. ncbi request reprint Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions
    Thomas W Geisbert
    Department of Viral Pathology and Ultrastructure, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Expert Rev Mol Med 6:1-24. 2004
    ..This review summarises our current understanding of EBOV pathogenesis and discusses various approaches to therapeutic intervention based on our current understanding of how EBOV produces a lethal infection...
  33. pmc Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates
    Chad E Mire
    Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA
    PLoS Negl Trop Dis 6:e1567. 2012
    ..These data strongly suggest that rVSV filovirus GP vaccine vectors lack the neurovirulence properties associated with the rVSV-wt parent vector and support their further development as a vaccine platform for human use...
  34. ncbi request reprint Towards a vaccine against Ebola virus
    Thomas W Geisbert
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702 5011, USA
    Expert Rev Vaccines 2:777-89. 2003
    ..This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development...
  35. ncbi request reprint Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers
    James W Leduc
    Institute for Human Infections and Immunity, Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas 77555 0610, USA
    Emerg Infect Dis 15:e1. 2009
    ....
  36. pmc Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus
    Chad E Mire
    Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
    PLoS Negl Trop Dis 7:e2600. 2013
    ....
  37. pmc Prospects for immunisation against Marburg and Ebola viruses
    Thomas W Geisbert
    Galveston National Laboratory1 and Department of Microbiology and Immunology2, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, USA
    Rev Med Virol 20:344-57. 2010
    ..The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure...
  38. pmc Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease
    Chad E Mire
    Galveston National Laboratory, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, USA
    Virol J 10:353. 2013
    ..Outbreaks have occurred in Malaysia, Singapore, India, and Bangladesh and have been associated with 40 to 75% case fatality rates. There are currently no vaccines or postexposure treatments licensed for combating human NiV infection...
  39. ncbi request reprint Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections
    Thomas W Geisbert
    Pathology Division, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    Virology 293:15-9. 2002
    ..Taken together with in vivo observations that early deaths were not observed in animals immunized with various viral vectors expressing EBOV GP, it is unlikely that any EBOV-enhancing antibodies profoundly affected EBOV pathogenesis...
  40. ncbi request reprint Exotic emerging viral diseases: progress and challenges
    Thomas W Geisbert
    Virology Division, US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Maryland 21702 5011, USA
    Nat Med 10:S110-21. 2004
    ..Of equal importance, these comparisons highlight critical gaps in our knowledge of these pathogens...